Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF614 vs OxyContin in Healthy Subjects
NCT02454712Phase 1Completed
- Sponsor
- Ensysce Biosciences
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of PF614 in pain (3 arms), sponsored by Ensysce Biosciences. Primary endpoint: Safety at 30 days. Started Nov 2016; status: completed.
02
Drugs
PF614
03
Conditions
pain
Beyond the preview
Go deeper on NCT02454712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454712.